<DOC>
	<DOCNO>NCT02499601</DOCNO>
	<brief_summary>The study objective demonstrate safety feasibility CORolla® TAA 12 month follow , evaluate performance therapy relieve symptom restore diastolic function patient heart failure preserve ejection fraction .</brief_summary>
	<brief_title>CORolla® TAA Heart Failure With Preserved Ejection Fraction ( HFpEF ) Diastolic Dysfunction ( DD )</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Failure , Diastolic</mesh_term>
	<criteria>Clinical criterion : 1 . Adult ( age &gt; 18 year ) 2 . Diagnosis heart failure preserve systolic function 3 . NYHA F. Class III IV symptom history least two previous heart failure hospitalization last year 4 . Able sign inform consent return followup visit . 5 . No contraindication anticoagulation antiplatelet treatment* 6 . Cardiovascular medication unchanged great 4 week ( include diuretic ) . 7 . Pulmonary Wedge pressure &gt; 15 mmHg document right heart catheterization enrollment . Echocardiography criterion : 8 . Left ventricular ejection fraction &gt; 50 % 9 . LV enddiastolic volume index ( LVEDVI ) &lt; 97 ml/m 2 10 . E/E ' ( mean septal lateral ) &gt; 12 ( applicable patient sinus rhythm ) . 11 . Left Atrial Volume Index : ( LAVi ml/m2 &gt; 29 ) . 12 . No evidence intracardiac thrombus . 13 . Minimal endocardial height Apex Mitral Annulus &gt; 60mm end systole . * In case doubt regard contraindication antiplatelet and/or anticoagulation therapy hematological evaluation conduct Exclusion Criteria Cardiovascular disease : 1 . Uncontrolled HTN define &gt; 160/90 mmHg patient 3drug therapy . 2 . Current anticipate need ICD , currently implant cardiac resynchronization device ( CRTD ) , leave ventricular assist device ( LVAD ) . 3 . Within past 3 month Acute myocardial infarction ( AMI ) , cerebral vascular accident ( CVA ) , Transient Ischemic Attack ( TIA ) , 4 . Coronary Artery Bypass Surgery ( CABG ) , valve replacement repair , aortic surgery percutaneous coronary intervention ( PCI transmyocardial laser revascularization ( TMR PMR ) ) past 3 month planned/anticipated within 6 month . 5 . Significant Valvular disease classify Moderate severe aortic stenosis/regurgitation Moderate severe mitral stenosis Severe mitral regurgitation 6 . History thrombus within previous 3 month . 7 . Hypertrophic cardiomyopathy 8 . History pericardial disease . 9 . HF attribute Cor pulmonale cause isolate right heart failure . 10 . Infiltrative heart disease . Noncardiovascular disease : 12 . Prior surgery , radiation , thoracic surgery limit ability place device . 13 . Asthma COPD ( e.g . FEV1 &lt; 1.5 liter ) , severe restrictive lung disease . 14 . Severe chronic renal failure indicate MDRD GFR &lt; 30 mL/min/1.73m2 15 . Liver impairment address bilirubin &gt; 2 mg/dl pseudocolinesterasis plasma concentration &lt; 1500 IU abnormal coagulative profile . 16 . Severe anemia address Hb concentration &lt; 9 gr/l . 17 . Solid organ hematologic transplant . 18 . Previous Trans Apical procedures/implantation . Miscellaneous condition : 19 . Unwilling fulfill protocol medication compliance , test , followup requirement . 20 . Comorbid condition physician 's opinion would prohibit subject 's ability meet protocol requirement . 21 . Pregnancy time enrollment . ( Women child bear potential must negative serum pregnancy test within two week prior enrollment , use hormonal contraceptive intrauterine device ) . 22 . Enrolled another treatment investigational study . 23 . A history alcohol abuse , drug addiction , psychosocial condition would preclude successful participation , clear judgment inform consent opinion Principal Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Heart Failure Preserved Ejection Fraction ( HFpEF )</keyword>
	<keyword>Heart Failure ( HF )</keyword>
	<keyword>New York Heart Association functional Class ( NYHA f. Cl )</keyword>
</DOC>